NCT04711356View on ClinicalTrials.gov

Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

September 17, 2021

Study Completion Date

March 31, 2022

Conditions
Ebola Virus Disease
Interventions
DRUG

Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection

Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein

Trial Locations (1)

Unknown

EBOVAC Kambia 1 clinic, Kambia

All Listed Sponsors
collaborator

Innovative Medicines Initiative

OTHER

collaborator

University of Sierra Leone

OTHER

lead

London School of Hygiene and Tropical Medicine

OTHER